Mr. Geoff Benic reports

ALTROVA HEALTH ANNOUNCES PROPOSED DEBT SETTLEMENT

Altrova Health Inc. has proposed to enter into debt settlement agreements with three consultants to settle aggregate indebtedness of $215,000 through the issuance of an aggregate of 3,583,333 common shares of the company at a deemed price of six cents per share.

The debt settlement is intended to reduce the company's outstanding liabilities and preserve cash for working capital purposes. Completion of the debt settlement remains subject to the receipt of all required regulatory approvals, including the approval of the Canadian Securities Exchange (the CSE) and the satisfaction of other customary closing conditions. The common shares issued pursuant to the debt settlement will be subject to a statutory hold period of four months and one day from the date of issuance, in accordance with applicable securities laws and the policies of the CSE.

About Altrova Health Inc.

Altrova Health is a Canadian public company building a growing portfolio of health solutions across detection, protection, treatment and wellness. The company's current product portfolio includes exclusive Canadian distribution rights for the Nirlab SA Nirlight drug analysis device, the O-Spray product line and the rapid detection strip portfolio of its subsidiary Drug Lab 118 Ltd.

We seek Safe Harbor.